MARKET

STAB

STAB

Statera BioPharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.880
-0.050
-1.71%
Opening 10:44 09/21 EDT
OPEN
2.950
PREV CLOSE
2.930
HIGH
2.960
LOW
2.790
VOLUME
31.93K
TURNOVER
--
52 WEEK HIGH
10.97
52 WEEK LOW
1.854
MARKET CAP
73.87M
P/E (TTM)
-15.1499
1D
5D
1M
3M
1Y
5Y
Statera Biopharma, Inc. to Participate in the Cantor Virtual Global Healthcare Conference
Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, will participate in the 2021 Cantor Virtual Global Healthcare Conference taking place Se...
PR Newswire · 3h ago
Statera BioPharma, Inc. to Ring Nasdaq Stock Market Closing Bell
Statera BioPharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that President and CEO Michael K. Handley and other members of the manag...
PR Newswire · 09/09 17:08
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) —
Benzinga · 09/08 11:55
72 Biggest Movers From Yesterday
Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.
Benzinga · 09/08 08:57
Statera BioPharma: The Ticker Formerly Known as CBLI
On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets. 
Benzinga · 09/07 12:06
Statera BioPharma Provides Update On Integration Of ImQuest
Statera BioPharma, Inc. Provides Update on Integration of ImQuest FORT COLLINS, Colo., Sept. 1, 2021 /PRNewswire/ -- Statera BioPharma (NASDAQ:STAB), a leading biopharmaceutical company creating
Benzinga · 09/01 13:25
Statera BioPharma, Inc. Provides Update on Integration of ImQuest
/PRNewswire/ --  (NASDAQ: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update on the integration of the ImQuest BioSciences business unit and the st...
PR Newswire - PRF · 09/01 13:20
BRIEF-Cytocom Plans To Adopt New Corporate Name "Statera Biopharma, Inc."
reuters.com · 08/31 11:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of STAB. Analyze the recent business situations of Statera BioPharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 26
Institutional Holdings: 787.69K
% Owned: 3.07%
Shares Outstanding: 25.65M
TypeInstitutionsShares
Increased
5
79.44K
New
3
36.68K
Decreased
4
322.64K
Sold Out
4
73.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.21%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Non-Executive Chairman/Independent Director
Lea Verny
President/Chief Executive Officer/Director
Michael Handley
Chief Financial Officer
Peter Aronstam
Chief Operating Officer/Director
Taunia Markvicka
Chief Technology Officer
Robert Buckheit
Vice President - Finance
Christopher Zosh
Other
Cozette Mcavoy
Other
Clifford Selsky
Director
Steve Barbarick
Independent Director
Randy Saluck
No Data
About STAB
Statera BioPharma, Inc., formerly Cytocom, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies targeting autoimmune, neutropenia/anemia, viruses and cancers. Its Advanced Immunomodulating Multi-component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200, STAT-400 and STAT-600 AIMS programs. Its STAT-200 program includes STAT-201, STAT-205, STAT-203 and STAT-202. STAT-201 is focused the treatment of Crohn’s disease. STAT-205 is focused on treatment of acute and post-acute coronavirus (COVID 19). Its STAT-400 programs include STAT-401 and STAT-400. STAT-401 is an injectable pentapeptide that is targeted for patients with pancreatic cancer.

Webull offers kinds of Statera Biopharma Inc stock information, including NASDAQ:STAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading STAB stock methods without spending real money on the virtual paper trading platform.